Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented at the 39 th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna, Austria from October 17-21, 2026.

Dr. David N. Cade, Telix Group Chief Medical Officer, said, "Our expansive presence at EANM reflects the breadth and maturity of Telix's pipeline, spanning pivotal therapeutic studies, precision diagnostics and next-generation technologies. The selection of 12 abstracts for top-rated oral presentations is a strong recognition of the quality and clinical relevance of this work. We look forward to continuing this discussion at our sponsored symposium on the future of theranostics in urologic oncology."

Key presentations include the Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma, the Phase 3 LUTEON trial of TLX250-Tx in ccRCC, and interim results from the PTherpan-Lu trial of TLX597-Tx in mAPMR prostate cancer [1]. Topline Phase 3 data for TLX591-Px (Illuccix) PET [2] imaging of prostate cancer in Chinese men will also be presented, together with real-world experience with TLX250-Px (Zircaix [3]) in ccRCC, and research from our targeted alpha therapy and MedTech programs. As in previous years, Telix will support the EANM Sanjiv Sam Gambhir Young Investigator Award, in memory of an extraordinary man and inspiring educator.

Visit booth #527 to explore opportunities for collaboration with Illuccix® (kit for the preparation of gallium-68 gozetotide injection), Telix's commercial PSMA-PET imaging [4] agent in Europe; our theranostic pipeline; and our medical technologies, including the SENSEI® miniature drop-in gamma probe, QDOSE® dosimetry software and artificial intelligence (AI).

Title: The future doesn't wait: The next era of theranostics in urologic oncology. Date & Time: 18-Oct-26, 13:15 – 14:45 Location: Hall F2, Austria Center Vienna Chair: J. Calais, Gustave Roussy, IGR and Université Paris-Saclay, Paris, France Agenda: The theranostic revolution

• J. Calais

The evolving role of PSMA-PET in prostate cancer

• K. Herrmann, University Hospital Essen, Germany

• M. Ghesani, United Theranostics, USA

Next-generation PSMA therapeutics: Overcoming today's challenges

• D. Oprea-Lager, Radboud University Medical Center, Nijmegen, the Netherlands

• L. Emmett, St Vincent's Hospital, Sydney, Australia

Panel discussion - all

Extending prostate cancer theranostic success to broader GU diseases

• J. Calais

Title: ELEGANCE, Prospective pilot study, assessing imaging performance of TLX250-Px ([⁸⁹Zr]Zr-girentuximab) PET/CT in Patients with Hepatocellular Carcinoma, Biliary Tract Cancer or Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (NCT06735560) Date and Time: 18-Oct-26, 08:00 – 09:30 Presenter: Clement Bailly, CHU Nantes Abstract #: OP-036

Title: HIMIKO, TLX591-Px ([⁶⁸Ga]Ga-PSMA) PET/CT in Hepatocellular Carcinoma: impact of Multiparametric dynamic whole-body imaging and kinetic modelling (NCT06999837) Date and Time: 18-Oct-26, 08:00 – 09:30 Presenter: Rachel Bardy, CHU Nantes Abstract #: OP-041

Title: Exploring carbonic anhydrase IX as a diagnostic imaging target using TLX250-Px ([⁸⁹Zr]Zr-girentuximab) in Von Hippel-Lindau Disease: preliminary results from the CAT-VHL Phase 2 trial (NCT07171905) Date and Time: 18-Oct-26, 15:00 – 16:30 Presenter: Fabrizia Gelardi, San Raffaele Hospital Abstract #: OP-168

Title: LUTEON, Phase 3 study to assess safety and efficacy of TLX250-Tx (¹⁷⁷Lu-girentuximab) in advanced, relapsed or recurrent ccRCC (NCT07197580) Date and Time: 18-Oct-26, 15:00 – 16:30 Presenter: Ghoufrane Tlili, CHU Bordeaux Abstract #: OP-170

Title: Building the traceability backbone for radiopharmaceutical therapy, first results from the PDIB Secondary Standards Laboratory Network Date and Time: 19-Oct-26, 08:00 – 09:30 Presenter: Steven Graves, University of Iowa Abstract #: OP-291

Title: Optimizing SPECT/CT for alpha emitters: Phantom validation and calibration of [²¹¹At] imaging Date and Time: 19-Oct-26, 08:00 – 09:30 Presenter: Rob van Rooij, UMC Utrecht Abstract #: OP-294

Title: IODO-RISE, TLX101-Tx (iodofalan-¹³¹I) in recurrent high-grade glioma, investigation of safety and efficacy Date and Time: 19-Oct-26, 08:00 – 09:30 Presenter: Tim Sturre, UMC Utrecht Abstract #: OP-311

Title: IPAX BrIGHT, Pivotal study of TLX101-Tx (iodofalan-¹³¹I) with or without lomustine vs lomustine alone for the treatment of patients with radiographically confirmed recurrent glioblastoma at first recurrence (NCT07100730) Date and Time: 19-Oct-26, 08:00 – 09:30 Presenter: Nelleke Tolboom, UMC Utrecht Abstract #: OP-312

Title: Comparative evaluation of TLX252-Tx ([²²⁵Ac]Ac-) and TLX250-Tx ([¹⁷⁷Lu]Lu-DOTA-hG250) targeted radionuclide therapy and combination with PD1 blockade in a preclinical renal cell carcinoma model Date and Time: 19-Oct-26, 16:45 – 18:15 Presenter: Twan van der Werff, UMC Radboud Abstract #: OP-478

Title: Interim results from PTherpan-Lu trial: TLX597-Tx ([¹⁷⁷Lu]Lu-panPSMA) radionuclide therapy for patients with mCRPC [5] Date and Time: 19-Oct-26, 16:45 – 18:15 Presenter: Yehia Omar, Misr Radiology Abstract #: OP-523

Title: Integration of spatial analysis and deep learning for enhanced tumor classification in total-body PET/CT imaging: using residual deep learning with spatial feature augmentation and cross-validated ensemble learning Date and Time: 20-Oct-26, 09:45 – 11:15 Presenter: Simon Wail, Telix Pharmaceuticals Abstract #: OP-613

Title: TLX250-Px ([⁸⁹Zr]Zr-girentuximab) PET/CT for characterization of indeterminate renal masses, diagnostic performance and clinical impact in a real-world cohort Date and Time: 20-Oct-26, 09:45 – 11:15 Presenter: Sazan Rasul, Medical University of Vienna Abstract #: OP-627

Title: QDOSE® allometry-guided human dosimetry of TLX102-Tx ([²¹¹At]APA): Impact of administration route on maximum tolerated activity Abstract #: EP-0067

Title: Illuccix China, preliminary results from Phase 3 trial of TLX591-Px (⁶⁸Ga-PSMA-11) PET for detection of biochemical recurrence of prostate cancer in Chinese men (NCT05847348) Abstract #: EP-0460

Title: Impact of TLX250-Px (⁸⁹Zr-girentuximab) based radionuclide imaging in patients with renal cell carcinoma on virtual tumor board decision making Abstract #: EP-0606

Title: A semi-mechanistic population biodistribution model of TLX250-Px (⁸⁹zr-girentuximab) for the diagnosis of clear cell renal cell carcinoma Abstract #: EP-0999

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

Telix's commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA) for prostate imaging, and Pixclara® (floretyrosine F 18) approved by the FDA for glioma imaging. The Company's late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (177 Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (iodofalan 131 I) in recurrent glioblastoma, and TLX250-Tx (lutetium (177 Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Eliza Schleifstein 917.763.8106 (Mobile) [email protected]

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, including TLX250-Px, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

[1] Metastatic androgen pathway modulation-resistant prostate cancer (formerly known as metastatic castration-resistant prostate cancer, or mCRPC).

[2] Positron emission tomography.

[3] Brand name subject to final regulatory approval.

[4] Imaging of prostate-specific membrane antigen with positron emission tomography.

[5] Also known as mAPMR.